Venture Partner

• Jul 2022 - Present

Tiger Jade Capital is a healthcare-focused private equity firm which is an independent and strategic fund initiated by two founding partners and Dr. Ye Xiaoping, Chairman of Hangzhou Tigermed Consulting Co. Ltd., with a focus to create long-term value for LPs in healthcare and life science related sectors. We can leverage Tigermed's unparalleled ecosystem, which concurrently runs 500+ clinical trial programs, serving over 300+ innovative companies globally. Tiger Jade Capital is a healthcare-focused private equity firm which is an independent and strategic fund initiated by two founding partners and Dr. Ye Xiaoping, Chairman of Hangzhou Tigermed Consulting Co. Ltd., with a focus to create long-term value for LPs in healthcare and life science related sectors. We can leverage Tigermed's unparalleled ecosystem, which concurrently runs 500+ clinical trial programs, serving over 300+ innovative companies globally.

Incubio Assessment Panel

• Jul 2022 - Present

The Incu-Bio Programme at the Hong Kong Science and Technology Park (HKSTP) is a 4-year programme offered by the HKSTP that aims to support the growth and development of biomedical tech startups in Hong Kong. The Incu-Bio Programme at the Hong Kong Science and Technology Park (HKSTP) is a 4-year programme offered by the HKSTP that aims to support the growth and development of biomedical tech startups in Hong Kong.

Managing Partner

• Oct 2017 - Present

Bioworld Ventures invests globally in innovative companies at the intersection of biology and technology, and currently has a portfolio of 10 investments. Bioworld Ventures invests globally in innovative companies at the intersection of biology and technology, and currently has a portfolio of 10 investments.

Director, BD / VC

• Jan 2021 - Mar 2022

Executed Genesis' first venture investment (CorVent) and asset purchase (Chocolate Touch DCB) and structured equity-license deal (SafeHeal). Deal quarterback for BD responsible for deal sourcing, due diligence, deal structure, licensing structure, financial models and NPV analyses and investment recommendation. Scope of deals included technology/IP licensing, tech transfer, research collaboration agreements, venture investments, asset purchases, acqui-hires, and venture creations.

Director, R&D

• Sep 2019 - Jan 2021

Executed Genesis's first R&D partnerships and set the template for external collaboration, one that was used for 6 subsequent projects. Defined cross-divisional R&D and business process flow. Created version 1 documents for R&D development, including project plans, essential requirements and quality plans, design inputs and VOC and device development plans. Genesis Medtech Group is a Singapore-headquartered regional medical technology platform focused on minimally invasive therapies in vascular intervention and general surgery. Backed by Boyu Capital, Sequoia China, Wuxi Apptec, GIC and General Atlantic.

Board Advisor / Interim CEO

• Apr 2019 - Aug 2019

CytoAstra LLC has developed a new patented device called CytoPhone using a non-invasive, label-free in-vivo photoacoustic flow cytometry (PAFC) theranostic system for early detection and destruction of circulating tumour cells. The technology was featured on the cover of the June 12th edition of Science Translational Medicine, showing first-in-human clinical data in melanoma patients. CytoAstra LLC has developed a new patented device called CytoPhone using a non-invasive, label-free in-vivo photoacoustic flow cytometry (PAFC) theranostic system for early detection and destruction of circulating tumour cells. The technology was featured on the cover of the June 12th edition of Science Translational Medicine, showing first-in-human clinical data in melanoma patients.

Portfolio Manager

• Dec 2017 - Jan 2019

Sectoral Asset Management Inc. is a global healthcare specialist investment fund managing both public and private equity portfolios with over $1bn in assets under management. Sectoral maintains offices in Montreal, Geneva, and Hong Kong.www.sectoral.com

Financial Analyst

• Aug 2015 - Nov 2017

VP Operations, Business Development

• Sep 2014 - Apr 2015

Built initial soft and hard company infrastructure and oversaw the fit-out of a wet lab. Conducted technology licensing negotiations and patent portfolio management, improvement and iteration of company business strategy, management of research and development operations and was the lead in executing partnerships. The latter included a research collaboration agreement with Pfizer. Novoheart is a stem cell biotechnology startup that is dedicated to develop and engineer bio-artificial human heart prototypes using a combination of stem cell and tissue engineering approaches.http://www.novoheart.com

Investment Analyst

• Jan 2011 - Aug 2014

Conducted equity research and analysis, ideas generation, financial modelling and valuations for the pharmaceutical / medtech, financial and consumer sector companies. Primary author for the monthly investor newsletters and monthly reports for two funds with a distribution list of 100+ investors. Winnington Capital is a Hong Kong-based Asian alternative fund manager, founded in 2001.www.winnington.net Conducted equity research and analysis, ideas generation, financial modelling and valuations for the pharmaceutical / medtech, financial and consumer sector companies. Primary author for the monthly investor newsletters and monthly reports for two funds with a distribution list of 100+ investors. Winnington Capital is a Hong Kong-based Asian alternative fund manager, founded in 2001.www.winnington.net

R&D Manager

• Jul 2008 - Oct 2010

Managed a project team of over 10 full time staff across R&D, quality, manufacturing and testing as the newly formed Advanced Biomaterials Group. Point person for all stakeholders across 3 divisions at Stryker (Trauma, CranioMaxilloFacial and Orthopaedics). Had approval authority through the entire new product development process, including design freeze, design verification and validation, process design, optimisation, scale up and validation, design transfer, 510(k) regulatory approvals, product launch and post-launch monitoring in both Orthopaedics and Interventional Spine. Managed the bilingual, cross-border working relationship and upstream manufacturing process with an aerospace manufacturer for Stryker's newest flagship hip stem implant.Stryker is a Fortune 500 medical technology company offering a diverse range of innovative technologies, including reconstructive, medical and surgical, neurotechnology and spine products.www.stryker.com

Project Engineer

• Dec 2007 - Jul 2008

Design Engineer

• Jul 2006 - Dec 2007

Biomedical Engineer

• Aug 2005 - Jul 2006

Inner-Pulse, previously known as IRM Inc, is a biomedical startup company primarily engaged in the development of disruptive cardiac rhythm management solutions. Funded by Johnson and Johnson, Boston Scientific, Frazier Healthcare, Delphi Ventures and Synergy Life Science Partners. Conducted product design and design verification testing for an implantable defibrillator, and created design control procedures with the Head of R&D Inner-Pulse, previously known as IRM Inc, is a biomedical startup company primarily engaged in the development of disruptive cardiac rhythm management solutions. Funded by Johnson and Johnson, Boston Scientific, Frazier Healthcare, Delphi Ventures and Synergy Life Science Partners. Conducted product design and design verification testing for an implantable defibrillator, and created design control procedures with the Head of R&D

Electrocardiology Lab Analyst

• May 2004 - Aug 2005

Undergraduate researcher in Wanda Krassowska Neu's lab Undergraduate researcher in Wanda Krassowska Neu's lab